The transdermal device according to claim 4, wherein said elastomeric polymer is selected from the group consisting of silicone polymers, polyisobutylene and siliconepolyethyleneoxide copolymers.Ħ. The transdermal device according to claim 1, wherein said polymer in said reservoir wall is an elastomeric polymer.ĥ. The transdermal device according to claim 1, wherein said therapeutic agent is dexmedetomidine.Ĥ. The transdermal device according to claim 1, wherein said cyclodextrin derivative is 2-hydroxypropyl-β-cyclodextrin or 2-hydroxypropyl-γ-cyclodextrin.ģ.
Wherein the conversion of said solid-state pH-adjusting agent to the buffer solution determines the unionization of said therapeutic agent.Ģ. Wherein said reservoir wall comprises a polymer, wherein said polymer is substantially impermeable to the ionized form or to the inclusion complex of said therapeutic agent but is permeable to water and to the unionized form of said therapeutic agent, (c) a cyclized polysaccharide selected from the group consisting of a cyclodextrin, a cyclodextrin derivative, and a cyclodextrin polymer, wherein said cyclized polysaccharide is capable of improving the solubility of said therapeutic agent in the buffer solution by forming an inclusion complex with said therapeutic agent and (b) a solid-state pH-adjusting agent, wherein said agent is converted to a buffer solution upon uptake of water, and (a) said therapeutic agent in the form of a solid-state salt, A controlled release transdermal device for the delivery of a therapeutic agent, comprising a reservoir and a reservoir wall,
0 kommentar(er)
